Cecilia Cirelli

Dr. Cecilia Cirelli

Chelsea and Westminster Hospital, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2024 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
APAlessandra Preziosi
Alessandra Preziosi
Cecilia CirelliCecilia Cirelli
Cecilia Cirelli
DWDale Waterhouse
Dale Waterhouse
LPLaura Privitera
Laura Privitera
PCPaolo De Coppi
Paolo De Coppi
Stefano GiulianiStefano Giuliani
Stefano Giuliani
Background: Medical devices for fluorescence-guided surgery (FGS) are becoming available at a fast pace. The main challenge for surgeons lies in the lack of in-depth knowledge of optical imaging, different technical specifications and poor standardisation, and the selection of the best device based on clinical application. Methods: This manuscript aims to provide an up-to-date description of the commercially available fluorescence imaging platforms by comparing their mode of use, required settings, image types, compatible fluorophores, regulatory approval, and cost. We obtained this information by performing a broad literature search on PubMed and by contacting medical companies directly. The data for this review were collected up to November 2023. Results: Thirty-two devices made by 19 medical companies were identified. Ten systems are surgical microscopes, 5 can be used for both open and minimally invasive surgery (MIS), 6 can only be used for open surgery, and 10 only for MIS. One is a fluorescence system available for the Da Vinci robot. Nineteen devices can provide an overlay between fluorescence and white light image. All devices are compatible with Indocyanine Green, the most common fluorescence dye used intraoperatively. There is significant variability in the hardware and software of each device, which resulted in different sensitivity, fluorescence intensity, and image quality. All devices are CE-mark regulated, and 30 were FDA-approved. Conclusion: There is a prolific market of devices for FGS and healthcare professionals should have basic knowledge of their technical specifications to use it at best for each clinical indication. Standardisation across devices must be a priority in the field of FGS, and it will enhance external validity for future clinical trials in the field. Graphical

Holly BlakeHolly Blake
Holly Blake
JCJessica Corner
Jessica Corner
Cecilia CirelliCecilia Cirelli
Cecilia Cirelli
Juliet HassardJuliet Hassard
Juliet Hassard
LBLydia Briggs
Lydia Briggs
JBJonathan Ball
Jonathan Ball
We aimed to explore student and staff perceptions and experiences of a pilot SARS-CoV-2 asymptomatic testing service (P-ATS) in a UK university campus setting. This was a mixed-method study comprised of an online survey, and thematic analysis of qualitative data from interviews and focus groups conducted at the mid-point and end of the 12-week P-ATS programme. Ninety-nine students (84.8% female, 70% first year; 93.9% P-ATS participants) completed an online survey, 41 individuals attended interviews or focus groups, including 31 students (21 first year; 10 final year) and 10 staff. All types of testing and logistics were highly acceptable (virus: swab, saliva; antibody: finger prick) and 94.9% would participate again. Reported adherence to weekly virus testing was high (92.4% completed ≥6 tests; 70.8% submitted all 10 swabs; 89.2% completed ≥1 saliva sample) and 76.9% submitted ≥3 blood samples. Students tested to “keep campus safe”, “contribute to national efforts to control COVID-19”, and “protect others”. In total, 31.3% had high anxiety as measured by the Generalized Anxiety Disorder scale (GAD-7) (27.1% of first year). Students with lower levels of anxiety and greater satisfaction with university communications around P-ATS were more likely to adhere to virus and antibody tests. Increased adherence to testing was associated with higher perceived risk of COVID-19 to self and others. Qualitative findings revealed 5 themes and 13 sub-themes: “emotional responses to COVID-19”, “university life during COVID-19”, “influences on testing participation”, “testing physical and logistical factors” and “testing effects on mental wellbeing”. Asymptomatic COVID-19 testing (SARS-CoV-2 virus/antibodies) is highly acceptable to students and staff in a university campus setting. Clear communications and strategies to reduce anxiety are likely to be important for testing uptake and adherence. Strategies are needed to facilitate social connections and mitigate the mental health impacts of COVID-19 and self-isolation.

23 July 2022 in BMC Public Health
Verified
Journal Article
Open access
PDF file
SSSarah Somerset
Sarah Somerset
WJWendy Jones
Wendy Jones
CECatrin Evans
Catrin Evans
Cecilia CirelliCecilia Cirelli
Cecilia Cirelli
DMDouglas Mbang
Douglas Mbang
Holly BlakeHolly Blake
Holly Blake
Late diagnosis of HIV remains a challenge, despite improved testing and treatment. Testing is often targeted at high-risk groups; workplace events might normalise testing and allow access to a wider population. The construction workforce has a number of risk factors for HIV. In the Test@Work study, HIV tests were delivered within general health checks to construction employees, with high uptake and acceptability. This paper reports on the experiences of construction managers and health professionals involved in Test@Work and explores the suitability of construction worksites as a venue for opt-in HIV testing. Qualitative interviews (n = 24) were conducted with construction managers who had facilitated health check/HIV testing (n = 13), and delivery partners (n = 11) including i) healthcare volunteers who had delivered general health checks (n = 7) and, ii) HIV professionals who had conducted HIV testing (n = 4) at 21 Test@Work events held on construction sites. Interviews explored their experiences of these events and views towards HIV testing in the workplace. Exit questionnaires (n = 107) were completed by delivery partners after every event, providing qualitative data identifying facilitators and barriers to effective delivery. Thematic analysis identified themes that were mapped against a socioecological framework. Delivery partners reported high engagement of construction workers with workplace HIV testing, peer-to-peer encouragement for uptake, and value for accessibility of onsite testing. HIV professionals valued the opportunity to reach an untested population, many of whom had a poor understanding of their exposure to HIV risk. Managers valued the opportunity to offer workplace health checks to employees but some identified challenges with event planning, or provision of private facilities. The construction sector is complex with a largely male workforce. Providing worksite HIV testing and education to an untested population who have poor knowledge about HIV risk helped to normalise testing, encourage uptake and reduce HIV-related stigma. However, there are practical barriers to testing in the construction environment. Rapid testing may not be the most suitable approach given the challenges of maintaining confidentiality on construction worksites and alternatives should be explored.

1 July 2021 in eClinicalMedicine
Verified
Journal Article
Open access
Jatinder HayreJatinder Hayre
Jatinder Hayre
Cecilia CirelliCecilia Cirelli
Cecilia Cirelli
MSMaulina Sharma
Maulina Sharma

20 September 2021 in Journal of the Royal Society of Medicine
Verified
Journal Article
Closed access
PDF file
Cecilia CirelliCecilia Cirelli
Cecilia Cirelli
Jatinder HayreJatinder Hayre
Jatinder Hayre
JAJackie Applebee
Jackie Applebee

1 February 2025 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Open access
PDF file
NMNeena Modi
Neena Modi
MCMohammad Chehrazi
Mohammad Chehrazi
JBJames Boardman
James Boardman
ABAlan Boyd
Alan Boyd
PBPeter Bradley
Peter Bradley
VCVictoria Cornelius
Victoria Cornelius
Background: Nutrition is essential for preterm brain development. Optimal nutrition is dependent upon gastrointestinal health. Primary objective: To form a multiprofessional collaboration to design the world’s first neonatal precision-medicine platform trial to test new and existing nutritional interventions for very preterm infants, to prevent and treat the serious gastrointestinal inflammatory disease necrotising enterocolitis and improve brain health and development. Participants: Infants born very preterm (< 32 weeks gestation). Data sources: Published literature; United Kingdom National Neonatal Research Database. Methods: Engagement with parents, patients, clinical teams, and industry; literature reviews; simulation studies; mechanistic study design; collaborative study development. Results: There was strong stakeholder support for the platform; seven interventions were selected from those proposed, four for immediate evaluation (pasteurised human donor milk; cow milk- and human milk-derived macronutrient fortifiers; probiotic), and three for subsequent incorporation (enteral arginine; enteral insulin; fluorescence image-guided surgery). We involved Australia/New Zealand neonatal units to shorten recruitment time, designed a precision-medicine platform trial, specified operational requirements and costs, developed engagement materials, and established parent–patient, independent scientific advisory and emerging investigator groups. Limitations: National Institute for Health and Care Research processes required stage 1 application submission 8 months into the Accelerated Development Award. This was unsuccessful and did not include an opportunity to respond to feedback. Conclusions: Stakeholders consider a neonatal precision-medicine platform trial a high priority, providing an efficient approach to establish the efficacy of treatments and the gestational age range of infants most likely to benefit, and to speed the pace of evidence generation to improve clinical care. Future work: Reapplication, requiring a further stage 1 application. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR153935.